CRV-101 / Curevo Vaccine - LARVOL DELTA

Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older (clinicaltrials.gov) - P2 | N=876 | Active, not recruiting | Sponsor: Curevo Inc | Trial primary completion date: Oct 2024 ➔ Mar 2025

Head-to-Head • Trial primary completion date • Herpes Zoster • Infectious Disease • Varicella Zoster • CD4

Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older (clinicaltrials.gov) - P2 | N=876 | Active, not recruiting | Sponsor: Curevo Inc | Recruiting ➔ Active, not recruiting | Trial primary completion date: Sep 2023 ➔ Oct 2024

Enrollment closed • Head-to-Head • Trial primary completion date • Herpes Zoster • Infectious Disease • Varicella Zoster • CD4

Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older (clinicaltrials.gov) - P2 | N=876 | Recruiting | Sponsor: Curevo Inc | Active, not recruiting ➔ Recruiting | Trial completion date: Nov 2028 ➔ Sep 2029 | Trial primary completion date: Nov 2022 ➔ Sep 2023

Enrollment open • Head-to-Head • Trial completion date • Trial primary completion date • Herpes Zoster • Infectious Disease • Varicella Zoster • CD4

Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older (clinicaltrials.gov) - P2 | N=678 | Active, not recruiting | Sponsor: Curevo Inc | Recruiting ➔ Active, not recruiting

Enrollment closed • Herpes Zoster • Infectious Disease • Varicella Zoster • CD4

Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older (clinicaltrials.gov) - P2 | N=678 | Recruiting | Sponsor: Curevo Inc

Head-to-Head • New P2 trial • Herpes Zoster • Infectious Disease • Varicella Zoster • CD4

Curevo will go head-to-head against GSK's Shingrix thanks to new $60M financing (FierceBiotech) - "Curevo Vaccine is hoping $60 million in financing will help the small biotech literally go head-to-head against GlaxoSmithKline's market-dominating shingles vaccine Shingrix. The new series A financing will fund a phase 2b head-to-head trial of Curevo's shingles vaccine CRV-101 against Shingrix. The biotech said the study will enroll 678 people with the cash supporting initiation through topline data."

Financing • Herpes Zoster • Infectious Disease

Curevo Vaccine Announces the Approval to Conduct a Phase 1b Clinical Trial in South Africa to Evaluate Safety and Immunogenicity of Its Adjuvanted Subunit Investigational Vaccine, CRV-101, Against Varicella (Chickenpox) in HIV-Positive Children (Businesswire) - P1, N=90; NCT03820414; Sponsor: Curevo Inc; "CRV-101 is currently being investigated for its safety, tolerability, immunogenicity, and effectiveness to prevent shingles in adults. Following a successful Phase 1 study, which showed low reactogenicity safety profile and a strong humoral and cellular immune response in healthy adults aged 18 to <50, a Phase 2 shingles clinical trial is scheduled to start in Q3 2021."

New P2 trial • P1 data • Herpes Zoster • Infectious Disease